Endogenous Glucocorticoid Response to Single-Dose Dexamethasone for Croup in Children: A Pharmacodynamic Study

Natasha Gill1,2, Natalie Sirizzotti1,2, David Johnson3

  • 1From the Children's Hospital, London Health Sciences Centre.

Insights

Single-dose oral dexamethasone for croup in children does not suppress endogenous corticosteroid levels. This common treatment for croup in children is not associated with adrenal insufficiency.

Area of Science:

  • Pediatric Endocrinology
  • Pharmacodynamics
  • Clinical Pharmacology

Background:

  • Dexamethasone is linked to adrenal insufficiency in children with chronic conditions.
  • Single-dose oral dexamethasone is the standard treatment for pediatric croup.
  • The impact of single-dose dexamethasone on adrenal function in croup is not well-established.

Purpose of the Study:

  • To investigate the association between single-dose oral dexamethasone and endogenous glucocorticoid levels in children with croup.
  • To test the hypothesis that dexamethasone causes a transient decrease in glucocorticoids.

Main Methods:

  • A prospective, two-arm pharmacodynamic study was conducted.
  • Participants included children over 2 years old with croup receiving dexamethasone and controls with upper respiratory infections.
  • The primary outcome measured was the urinary 6β-hydroxycortisol-cortisol ratio.

Main Results:

  • No significant differences in the change of 6β-hydroxycortisol-cortisol ratios were observed between the dexamethasone and control groups at any time point.
  • Median ratios in the dexamethasone group were 2.8 (baseline), 2.2 (morning), 2.0 (day 1), 2.8 (day 3), and 2.6 (day 7).
  • No serious adverse events or infectious complications were reported.

Conclusions:

  • Single-dose oral dexamethasone is not associated with decreased endogenous corticosteroid levels in children with croup.
  • Further research using criterion standard tests is recommended to definitively rule out hypothalamic-pituitary-adrenal axis suppression.
  • Future studies should also be adequately powered to detect adverse clinical outcomes.
Abstract

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...